Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LOXL2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LOXL2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LOXL2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00107172 | Oral cavity | NEOLP | regulation of epithelial to mesenchymal transition | 24/2005 | 99/18723 | 9.40e-05 | 1.15e-03 | 24 |
GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
GO:00614482 | Oral cavity | NEOLP | connective tissue development | 46/2005 | 252/18723 | 2.11e-04 | 2.25e-03 | 46 |
GO:001071811 | Oral cavity | NEOLP | positive regulation of epithelial to mesenchymal transition | 14/2005 | 52/18723 | 8.66e-04 | 6.83e-03 | 14 |
GO:004668821 | Oral cavity | NEOLP | response to copper ion | 12/2005 | 42/18723 | 1.13e-03 | 8.46e-03 | 12 |
GO:00020621 | Oral cavity | NEOLP | chondrocyte differentiation | 22/2005 | 106/18723 | 1.72e-03 | 1.19e-02 | 22 |
GO:0002040 | Oral cavity | NEOLP | sprouting angiogenesis | 32/2005 | 185/18723 | 4.29e-03 | 2.42e-02 | 32 |
GO:0051216 | Oral cavity | NEOLP | cartilage development | 32/2005 | 190/18723 | 6.44e-03 | 3.32e-02 | 32 |
GO:2000036 | Oral cavity | NEOLP | regulation of stem cell population maintenance | 9/2005 | 33/18723 | 6.45e-03 | 3.32e-02 | 9 |
GO:0070828 | Oral cavity | NEOLP | heterochromatin organization | 11/2005 | 46/18723 | 7.99e-03 | 3.95e-02 | 11 |
GO:000609134 | Thyroid | ATC | generation of precursor metabolites and energy | 256/6293 | 490/18723 | 6.55e-18 | 7.69e-16 | 256 |
GO:007048228 | Thyroid | ATC | response to oxygen levels | 193/6293 | 347/18723 | 1.83e-17 | 1.93e-15 | 193 |
GO:003629328 | Thyroid | ATC | response to decreased oxygen levels | 177/6293 | 322/18723 | 1.81e-15 | 1.32e-13 | 177 |
GO:000166628 | Thyroid | ATC | response to hypoxia | 169/6293 | 307/18723 | 6.58e-15 | 4.12e-13 | 169 |
GO:002290034 | Thyroid | ATC | electron transport chain | 106/6293 | 175/18723 | 2.20e-13 | 1.06e-11 | 106 |
GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
GO:000166731 | Thyroid | ATC | ameboidal-type cell migration | 228/6293 | 475/18723 | 3.72e-11 | 1.22e-09 | 228 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LOXL2 | SNV | Missense_Mutation | novel | c.199N>A | p.His67Asn | p.H67N | Q9Y4K0 | protein_coding | tolerated(0.24) | benign(0.087) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
LOXL2 | SNV | Missense_Mutation | | c.447N>C | p.Lys149Asn | p.K149N | Q9Y4K0 | protein_coding | tolerated(0.12) | benign(0.093) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
LOXL2 | insertion | In_Frame_Ins | novel | c.1901_1902insAAATGTGTGTTTAATTTGTTATTC | p.Val634_Phe635insAsnValCysLeuIleCysTyrSer | p.V634_F635insNVCLICYS | Q9Y4K0 | protein_coding | | | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
LOXL2 | deletion | Frame_Shift_Del | novel | c.1615delN | p.Ala539ProfsTer103 | p.A539Pfs*103 | Q9Y4K0 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LOXL2 | SNV | Missense_Mutation | rs768171524 | c.2212N>A | p.Gly738Ser | p.G738S | Q9Y4K0 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LOXL2 | SNV | Missense_Mutation | novel | c.877N>C | p.Asn293His | p.N293H | Q9Y4K0 | protein_coding | tolerated(0.32) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LOXL2 | SNV | Missense_Mutation | novel | c.1295N>G | p.Gln432Arg | p.Q432R | Q9Y4K0 | protein_coding | deleterious(0.03) | benign(0.009) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
LOXL2 | SNV | Missense_Mutation | novel | c.96N>A | p.His32Gln | p.H32Q | Q9Y4K0 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
LOXL2 | SNV | Missense_Mutation | rs748831417 | c.1322N>A | p.Arg441His | p.R441H | Q9Y4K0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
LOXL2 | SNV | Missense_Mutation | rs755780161 | c.2068C>T | p.Arg690Cys | p.R690C | Q9Y4K0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4017 | LOXL2 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GS-6624 | SIMTUZUMAB | |
4017 | LOXL2 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 385612245 | | |
4017 | LOXL2 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL2109667 | SIMTUZUMAB | |
4017 | LOXL2 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 385612244 | | |
4017 | LOXL2 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 252166622 | SIMTUZUMAB | |